Skip to main content
ABIVAX logo

ABIVAX — Investor Relations & Filings

Ticker · ABVX ISIN · FR0012333284 LEI · 969500D8TMNB184OJU95 PA Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2022-10-03 AGM Information
Country FR France
Listing PA ABVX

About ABIVAX

https://www.abivax.com

Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.

Recent filings

Filing Released Lang Actions
ABIVAX ANNOUNCES AD HOC ORDINARY AND EXTRAORDINARY GENERAL MEETING ON NOVEMBER 9, 2022
AGM Information Classification · 1% confidence The document is an announcement titled "ABIVAX ANNOUNCES AD HOC ORDINARY AND EXTRAORDINARY GENERAL MEETING ON NOVEMBER 9, 2022". It explicitly states that the preliminary meeting notice, which includes the agenda and proposed resolutions, was published in the official bulletin. This document serves to inform shareholders about the upcoming meeting, its purpose (renewing financial delegations and establishing incentive mechanisms), and where to find the full details. This content aligns perfectly with the definition of materials shared during an Annual General Meeting (AGM) or related preparatory/informational notices, which falls under the AGM-R code. Although it is an announcement, the core subject matter is the AGM itself, making AGM-R more specific than a general RPA or RNS.
2022-10-03 English
ABIVAX: Rapport Financier Semestriel 2022.
Interim / Quarterly Report Classification · 1% confidence The document is a 'Rapport Financier Semestriel 2022' (Half-Year Financial Report) for Abivax. It contains a detailed summary of activities, financial statements (balance sheet, income statement, cash flow), and management commentary for the first half of 2022. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H2 2022
2022-09-30 French
ABIVAX ANNONCE LA MISE A DISPOSITION DE SON RAPPORT FINANCIER SEMESTRIEL 2022
Report Publication Announcement Classification · 1% confidence The document is titled "ABIVAX ANNONCE LA MISE A DISPOSITION DE SON RAPPORT FINANCIER SEMESTRIEL 2022" (ABIVAX ANNOUNCES THE AVAILABILITY OF ITS 2022 SEMI-ANNUAL FINANCIAL REPORT). It explicitly states that the company has filed its 'Rapport Financier Semestriel 2022' (Semi-Annual Financial Report) with the AMF and provides links where the document is available. Since the text is short (2484 chars) and serves only to announce the publication of a report rather than containing the full report content, it fits the definition of a Report Publication Announcement (RPA). The underlying report itself would likely be classified as an Interim / Quarterly Report (IR), but this announcement is an RPA.
2022-09-30 French
ABIVAX ANNOUNCES THE RELEASE OF ITS 2022 HALF-YEAR FINANCIAL REPORT
Report Publication Announcement Classification · 1% confidence The document explicitly states: "ABIVAX ANNOUNCES THE RELEASE OF ITS 2022 HALF-YEAR FINANCIAL REPORT" and "Abivax... today announces the publication of its 2022 half-year financial report." The document itself is short (3919 chars) and primarily serves to announce that the actual report is available elsewhere (on the company website and the AMF website). This fits the definition of a Report Publication Announcement (RPA), which is used when the filing is an announcement about the release of a report, rather than the comprehensive report itself (which would likely be classified as IR for an Interim/Quarterly Report).
2022-09-30 English
Rapport CAC sur l'information financière semestrielle
Interim / Quarterly Report Classification · 1% confidence The document is a French-language financial report titled 'Rapport du commissaire aux comptes sur l'information financière semestrielle' (Auditor's report on semi-annual financial information) for ABIVAX, covering the period from January 1, 2022, to June 30, 2022. It includes the auditor's limited review conclusion and detailed financial statements (Balance Sheet and Income Statement) for the interim period. Since it contains substantive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H2 2022
2022-09-30 French
ABIVAX: ABSTRACT PORTANT SUR LES RESULTATS DE PHASE 2B D’OBEFAZIMOD SELECTIONNE POUR LA PRESENTATION D’UN POSTER LORS DU CONGRES UEG WEEK 2022
Regulatory Filings Classification · 1% confidence The document is a press release from Abivax announcing that an interim analysis of their Phase 2b study for Obefazimod (ABX464) in Ulcerative Colitis has been selected for a poster presentation at the UEG Week 2022 congress. It details the abstract information, the presentation time, and provides an update on the subsequent Phase 3 program. This type of announcement, which communicates key scientific/clinical data highlights and upcoming presentation schedules, aligns best with an Earnings Release (ER) if it were quarterly results, but since it is a specific scientific/clinical data update announcement, it is most closely related to an Investor Presentation (IP) or a general announcement. However, given the structure—a formal press release announcing scientific progress and upcoming conference participation, rather than a full financial report (10-K/IR) or a formal management discussion (MDA)—it functions as a high-level communication to investors about clinical milestones. Since there is no specific category for 'Clinical Trial Update Announcement', and it is not a full presentation (IP) or a general regulatory filing (RNS), the closest fit among the provided options that captures the essence of disseminating key operational/clinical news to the market is often grouped with Earnings Releases (ER) or Investor Presentations (IP). Given the focus is on scientific data selection and presentation, 'Investor Presentation' (IP) is a strong candidate if the content were the presentation itself. Since this is the *announcement* of the data being presented, and it contains forward-looking statements and clinical updates, it functions similarly to an Earnings Release (ER) in terms of market communication frequency, but ER is strictly for financial results. The document is a formal press release detailing clinical trial progress and conference participation. In the absence of a dedicated 'Clinical Trial Update' code, and noting it is not a short notice (Rule 2), it is a substantive communication. It is not a proxy statement (DEF 14A), a management discussion (MDA), or a full report (10-K/IR). It is a general announcement of scientific progress. Given the options, 'Regulatory Filings' (RNS) is the fallback, but 'Investor Presentation' (IP) often covers material updates intended for investors, even if it's just an announcement about one. However, this is a press release announcing a poster presentation, which is a form of corporate communication. I will classify this as a general announcement/regulatory filing (RNS) as it doesn't fit the specific financial/governance/report codes, although it is highly specific scientific news.
2022-09-27 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.